Etoposide toniribate - Mundipharma

Drug Profile

Etoposide toniribate - Mundipharma

Alternative Names: CAP7.1; EDO-S7.1; Etoposide prodrug (CAP7.1) - CellAct Pharma

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Institute for Medical Immunology Charite - Universitatsmedizin Berlin
  • Developer CellAct Pharma; Mundipharma EDO
  • Class Naphthols; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 30 Jan 2018 Chemical structure information added
  • 07 Aug 2017 CAP 7.1 licensed to Mundipharma EDO worldwide
  • 26 Apr 2017 CellAct Pharma terminates a phase II trial in Small cell lung cancer, Non-small cell lung cancer and Biliary cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (EudraCT2012-002378-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top